I just think it's an important piece of it because it seems like something is afoot here--that the manufacturers have--and drug companies have really been playing offense when it comes to 340B and I think it would be fair to take a look at their overcharges.
Castor expresses concern over drug manufacturers' practices regarding 340B overcharges.
Share & report
More from Kathy Castor
Mr. Chair, I urge my colleagues to vote ``yes.'' Please tank this bill which takes us backwards.
Sowing distrust in the scientific and medical communities is not a way to accomplish this goal.
We have not learned anything more about the origins of COVID-19, but we have learned a lot about NIH's diligent work.
These investments are smart. They are accelerating the use of American-made clean energy that is cheaper and more sustainable.
Other voices in this conversation
